KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Total Debt (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Total Debt for 16 consecutive years, with $35.3 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Debt changed 0.08% year-over-year to $35.3 billion, compared with a TTM value of $35.3 billion through Sep 2024, changed 0.08%, and an annual FY2023 reading of $34.9 billion, up 1.24% over the prior year.
  • Total Debt was $35.3 billion for Q3 2024 at Thermo Fisher Scientific, roughly flat from $35.4 billion in the prior quarter.
  • Across five years, Total Debt topped out at $35.6 billion in Q1 2024 and bottomed at $18.6 billion in Q2 2021.
  • Average Total Debt over 5 years is $29.0 billion, with a median of $33.3 billion recorded in 2022.
  • The sharpest move saw Total Debt decreased 11.9% in 2021, then skyrocketed 78.36% in 2022.
  • Year by year, Total Debt stood at $21.7 billion in 2020, then soared by 60.43% to $34.9 billion in 2021, then fell by 1.1% to $34.5 billion in 2022, then rose by 1.24% to $34.9 billion in 2023, then grew by 1.13% to $35.3 billion in 2024.
  • Business Quant data shows Total Debt for TMO at $35.3 billion in Q3 2024, $35.4 billion in Q2 2024, and $35.6 billion in Q1 2024.